Can pregabalin be prescribed to a 13-year-old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Pregabalin Be Given to a 13-Year-Old?

Yes, pregabalin can be given to a 13-year-old, but ONLY for partial-onset seizures as adjunctive therapy—it is NOT approved for pain conditions (neuropathic pain, fibromyalgia) in pediatric patients under 18 years of age. 1

FDA-Approved Pediatric Indications

The FDA label explicitly states that pregabalin is approved for:

  • Partial-onset seizures (adjunctive therapy): Ages 1 month and older 1
  • NOT approved for: Neuropathic pain (diabetic, postherpetic, spinal cord injury) or fibromyalgia in patients under 18 years 1

Dosing for a 13-Year-Old with Seizures

For a 13-year-old with partial-onset seizures, dosing depends on body weight:

  • If ≥30 kg: Start at 2.5 mg/kg/day, can increase to 10 mg/kg/day 1, 2
  • If <30 kg: Requires 40% higher dose (3.5-14 mg/kg/day) to achieve equivalent drug exposure 1, 3

The 10 mg/kg/day dose demonstrated statistically significant efficacy in reducing seizure frequency (21% greater reduction vs placebo, p=0.0185) in pediatric patients aged 4-17 years 1, 2. The 2.5 mg/kg/day dose showed numerical but not statistically significant improvement 1.

Safety Profile in Adolescents

Most common adverse effects (≥5%) in pediatric seizure trials 1, 2:

  • Somnolence (25.8% at 10 mg/kg/day)
  • Weight gain (13.4%)
  • Increased appetite (10.3%)

Critical safety warnings apply to all ages 1:

  • Suicidal thoughts/behavior (1 in 500 risk with antiepileptic drugs)
  • Serious breathing problems, especially with concurrent CNS depressants
  • Dizziness and sleepiness affecting daily activities
  • Allergic reactions (angioedema)

What About Pain Conditions in Adolescents?

Pregabalin is NOT FDA-approved for pain in pediatric patients. A 15-week trial in adolescents (ages 12-17) with fibromyalgia failed to show statistically significant benefit over placebo, despite numerical improvement 1. The safety profile was similar to adults, but efficacy was not established 1.

For neuropathic pain conditions (diabetic neuropathy, postherpetic neuralgia, spinal cord injury), there are no adequate studies in pediatric patients, and safety/effectiveness have not been established 1.

Clinical Decision Algorithm

For a 13-year-old patient:

  1. Is the indication partial-onset seizures?

    • YES → Pregabalin is appropriate as adjunctive therapy
    • NO → Pregabalin is NOT FDA-approved; consider alternative agents
  2. If seizures, what is the patient's weight?

    • ≥30 kg → Use standard pediatric dosing (2.5-10 mg/kg/day)
    • <30 kg → Increase dose by 40% (3.5-14 mg/kg/day)
  3. Screen for contraindications:

    • History of angioedema
    • Concurrent opioids or CNS depressants (increased respiratory depression risk)
    • History of substance abuse (pregabalin is Schedule V controlled substance)
    • Psychiatric history (increased suicidal ideation risk)
  4. If pain condition:

    • Do NOT use pregabalin off-label in this age group
    • Consider FDA-approved alternatives for pediatric pain management

Important Caveats

Juvenile animal toxicity data raise concerns 1: Rats exposed to pregabalin from early postnatal period through sexual maturity showed neurobehavioral abnormalities (learning/memory deficits, altered locomotor activity) and reproductive impairment at doses producing plasma exposures similar to human therapeutic doses. Some effects persisted after drug discontinuation, representing potential long-term consequences.

Renal dosing adjustments are mandatory: Pregabalin is renally eliminated, and dose reduction is required in renal impairment 4. This is particularly relevant in diabetic patients who may have concurrent nephropathy.

Gradual discontinuation is essential: Abrupt withdrawal can precipitate seizures and other serious problems 1. Taper slowly under medical supervision.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.